Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1978-1984

  Issa, Ala Y ^a   Volate, Suresh T ^a   Muga, Stephanie J ^b   Nitcheva, Daniela ^c   Smith, Theresa ^d   Wargovich, Michael I ^b,e  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c University of Columbia   (United States)

^d University of South Carolina   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CAFFEINE; CATECHIN; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; GALLIC ACID; GREEN TEA EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEA; TUMOR VOLUME; WESTERN BLOTTING;

ADENOMA; ANIMALS; AZOXYMETHANE; CAMELLIA SINENSIS; CARCINOGENS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLANT EXTRACTS;

EID: 34848902667     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm161     Document Type: Article

References (36)

1. Koo,M.W. et al. (2004) Pharmacological effects of green tea on the gastrointestinal system. Eur. J. Pharmacol., 500, 177-185.
2. Lee,M.J. et al. (2002) Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev., 11, 1025-1032.
3. Jung,Y.D. et al., (2001) EGCG, a major component of green tea, inhibits tumour growth by inhibiting. VEGF induction in human colon carcinoma cells. Br. J. Cancer, 84, 844-850.
4. Raederstorff,D.G., Schlachter,M.F., Elste,V., and Weber,P. (2003) Effect of EGCG on lipid absorption and plasma lipid levels in rats. J. Nutr. Biochem., 14, 326-332.
5. Tedeschi,E. et al. (2002) Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Ann. N. Y. Acad. Sci., 973, 435-437.
6. Yang,C.S. (1997) Inhibition of carcinogenesis by tea. Nature, 389, 134-435.
7. Yang,C.S. et al. (2001) Prevention of carcinogenesis by tea polyphenols. Drug Metab. Rev., 33, 237-253.
8. Yang,F. et al. (2001) The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol., 60, 528-533.
9. Arab,L. et al. (2003) The epidemiology of tea consumption and colorectal cancer incidence. J. Nutr., 133, 3310S-3318S.
10. Caderni,G. et al. (2000) Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis, 21, 1965-1969.
11. Chen,C. et al. (2003) Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis, 24, 1369-1378.
12. Lambert,J.D. et al. (2003) Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat. Res., 523-524, 201-208.
13. Min and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP). Mutat. Res. 506-507, 121-127.
14. Min mouse: Down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis, 24, 263-267.
15. Spencer J.P. (2003) Metabolism of tea flavonoids in the gastrointestinal tract. J. Nutr., 133, 3255S-3261S.
16. Chung,J.Y. et al. (2001) Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J., 15, 2022-2024.
17. Dong,Z. et al. (1997) Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res., 57, 4414-4419.
18. Liang,Y.C. et al. (1997) Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J. Cell Biochem. 67, 55-65.
19. McLoughlin,P. et al. (2004) Transcriptional responses to epigallocatechin-3 gallate in HT 29 colon carcinoma spheroids. Genes Cells, 9, 661-669.
20. Park, A.M. et al. (2003) Signal transduction pathways: Targets for green and black tea polyphenols. J. Biochem. Mol. Biol., 36, 66-77.
21. Zhao,Y. et al. (2004) Induction of apoptosis by epigallocatechin-3-gallate via mitochondrial signal transduction pathway. Prev. Med., 39, 1172-1179.
22. Yang,C.S. et al. (2002) Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol., 42, 25-54.
23. Hao,X.P. et al. (2001) Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res., 61, 8085-8088.
24. Volate,S.R. et al. (2005) Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis, 26, 1450-1456.
25. Ahmad,N. et al. (2000) Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys. 376, 338-346.
26. Bushman,J.L. (1998) Green tea and cancer in humans: A review of the literature. Nutr. Cancer, 31, 151-159.
27. Dashwood,R.H. et al. (1999) Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Proc. Soc. Exp. Biol. Med., 220, 239-243.
28. Blot,W.J. et al. (1996) Tea and cancer: A review of the epidemiological evidence. Eur. J. Cancer Prev., 5, 425-438.
29. Borrelli,F. et al. (2004) Systematic review: Green tea and gastrointestinal cancer risk. Aliment. Pharmacol. Ther., 19, 497-510.
30. Yang,C.S. et al. (2000) Mechanisms of inhibition of carcinogenesis by tea. Biofactors, 13, 73-79.
31. US Food and Drug Administration (2004), Qualified Health Claim Petition (Docket No. 2004Q-0083).
32. Hussain,T. et al. (2005) Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int. J. Cancer 113, 660-669.
33. Gupta, R.A. et al. (2002) Controversy: PPARgamma as a target for treatment of colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol., 283, G266-G269.
34. Bruce,W.R. (2003) Counterpoint: From animal models to prevention of colon cancer. Criteria for proceeding from preclinical studies and choice of models for prevention studies. Cancer Epidemiol. Biomarkers Prev., 12, 401-404.
35. Min mouse. Cancer Res., 60, 5434-5440.
36. Paulsen J.E. et al. (2001) Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res., 61, 5010-5015.